In this study, in order to investigate the potential of the novel polysaccharide sacran from Aphanothece Sacrum for development of atopic dermatitis (AD), we evaluated the potential of pretreatment with topical sacran to prevent the development of hapten (dinitrofluorobenzene: DNFB)-induced AD-like disease in mice. In the AD model mice, sacran markedly ameliorated AD symptoms such as scratching behavior and edema in ear. In addition, sacran significantly increased water content of the stratum corneum which regulates the skin barrier function. Furthermore, sacran significantly inhibited inflammatory cytokine and chemokine mRNA levels in the dermatitis skin as well as the IgE antibody level in serum. Sacran inhibited inflammatory cytokines mRNA production from Jurkat cells derived from human leukemia T cells after stimulation with phorbol 12-myristate 13-acetate/ionomycin. Meanwhile, sacran did not inhibit the proliferation of primary B cells stimulated with lipopolysaccharide. These results suggest that sacran has good anti-allergic effect on AD model mice, probably due to the amelioration of skin barrier function and suppression of immune responses.
Keywords: Anti-inflammation; Atopic dermatitis; Polysaccharides; Sacran.
Copyright © 2017 Elsevier B.V. All rights reserved.